期刊
BIOMEDICINES
卷 10, 期 12, 页码 -出版社
MDPI
DOI: 10.3390/biomedicines10123029
关键词
glioma; biomarkers; genomics; prognosis; cost-effectiveness; precision medicine
资金
- NCI NIH intramural program
- [ZID BC 010990]
This article reviews the clinically relevant molecular features and current cost of care for glioma patients, highlighting the promising direction of precision medicine using artificial intelligence approaches in glioma treatment.
Gliomas are the most common and aggressive primary brain tumors. Gliomas carry a poor prognosis because of the tumor's resistance to radiation and chemotherapy leading to nearly universal recurrence. Recent advances in large-scale genomic research have allowed for the development of more targeted therapies to treat glioma. While precision medicine can target specific molecular features in glioma, targeted therapies are often not feasible due to the lack of actionable markers and the high cost of molecular testing. This review summarizes the clinically relevant molecular features in glioma and the current cost of care for glioma patients, focusing on the molecular markers and meaningful clinical features that are linked to clinical outcomes and have a realistic possibility of being measured, which is a promising direction for precision medicine using artificial intelligence approaches.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据